In addition, recent findings have revealed that PIK3CA-mutated HER2+ BC patients less likely achieved pCR and prolonged DFS upon neoadjuvant anthracycline-taxane chemotherapy when combined with anti-HER2 treatment, and this might explain such discrepancy [31, 32]. Here, PIK3CA is linked to breast cancer.